Fate Therapeutics reported Q4 and FY2025 results, highlighting progress in its off-the-shelf CAR T-cell programs for autoimmune diseases and oncology, particularly FT819 and FT836. The company emphasized advancements in outpatient treatment capabilities and the potential to eliminate conditioning chemotherapy, supported by a strong cash position and reduced operating expenses, projecting runway through 2027.
FT819 successfully treated as outpatient therapy, eliminating the need for extended hospital stays and improving patient access.
positiveFT836 demonstrated clinical activity in colorectal cancer patients without the use of conditioning chemotherapy, with one patient showing a greater than 50% reduction in CEA levels.
positiveProjected operating runway through year-end 2027, supported by $205.1 million in cash, cash equivalents, and investments.
positiveOperating expenses reduced by 30% in 2025 compared to 2024.
positiveRevenue for Q4 2025 was $1.4 million, a decrease from $1.9 million in Q4 2024.
negativeNet loss for Q4 2025 was $32.4 million, or $0.27 per share, compared to a net loss of $52.2 million, or $0.44 per share, in Q4 2024, indicating continued significant losses.
negativeTotal operating expenses for Q4 2025 were $36.1 million, a decrease from $63.6 million in Q4 2024, but still represent a substantial burn rate.
attentionFull year 2025 revenue was $6.6 million, down from $13.6 million in full year 2024.
negativeFull year 2025 net loss was $136.3 million, or $1.15 per share, compared to a net loss of $186.3 million, or $1.64 per share, in full year 2024.
negativeMargin metrics will be available once backend extracts data from insights_json
Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.
Progress in bringing FT819 off-the-shelf CAR T cells as outpatient therapy, uniquely expanding autoimmune patient access.
Continuing to progress towards commencement of the first planned Phase 2 clinical trial in lupus nephritis.
Additional clinical signals across autoimmune disease and in oncology without the use of conditioning chemotherapy are further validating the breadth of our platform.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.